Prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic population aged ≥ 65 years by lipid-lowering medication use status

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 142-149

  Candrilli, Sean D ^a   Kuznik, Andreas ^b   Mendys, Philip M ^b   Wilson, Daniel J ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER INC   (United States)

Author keywords

Cardiovascular risk; Dyslipidemia; Elderly; Statins; Undertreatment

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONGESTIVE HEART FAILURE; DATA ANALYSIS; DIABETES MELLITUS; DRUG USE; DYSLIPIDEMIA; FEMALE; HEALTH CARE NEED; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PREVALENCE; RISK ASSESSMENT; STROKE; BLOOD; CORONARY ARTERY DISEASE; HEART FAILURE; UNITED STATES;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HEALTH SURVEYS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PREVALENCE; STROKE; UNITED STATES;

EID: 78049492834     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2211     Document Type: Article

References (23)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
2. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.
3. Alexander KP, Newby LK, Cannon CP, et al; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2549-2569.
4. Ray KK, Bach RG, Cannon CP, et al; PROVE IT TIMI-22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006;27(19):2310-2316.
5. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
6. Poulter NR, Dalhöf B, Sever PS, Wedel H, Collier DJ. Impact of atorvastatin on cardiovascular events in 4445 men and women aged 65 years and older: evidence from the Anglo-Scandinavian Outcomes trial-lipid-lowering arm. Stroke. 2006;37(2):695.
7. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol. 2001;87(5):646-649, A610.
8. Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154(3):554-560.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.
10. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm. Accessed May 10, 2010.
11. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147(1):1-9.
12. Koren MJ, Feldman T, Mendes RA. Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clin Cardiol. 2009;32(5):256-263.
13. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged, 65 versus. or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol. 2009;103(5):577-582.
14. Chaturvedi S, Zivin J, Breazna A, et al; SPARCL Investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009;72(8):688-694.
15. Neil HA, DeMicco DA, Luo D, et al; CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29(11):2378-2384.
16. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462-467.
17. Collier DJ, Poulter NR, Dalhof B, Sever PS, Wedel H. Impact of atorvastatin on cardiovascular events in 4445 men and women aged 65 years and older: evidence from the Anglo-Scandinavian Outcomes trial-lipid-lowering arm. Poster presented at: International Stroke Conference, February 16-18, 2006; Kissimmee, FL.
18. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453-462.
19. Kuller LH, Arnold AM, Psaty BM, et al. 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med. 2006;166(1):71-78.
20. Yan AT, Yan RT, Tan M, et al; Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119(8):676-683.
21. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17(2):92-100.
22. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645.
23. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461.